Abstract
Aspirin (ASA) hypersensitivity comprises types I to III (Cox-1 mediated) and types IV and V (IgE antibody mediated). Rapid, low-dose (81-325 mg/day) ASA desensitization regimens are known to be useful in establishing ASA tolerance in patients with coronary artery disease and coexisting ASA/nonsteroidal anti-inflammatory drug hypersensitivity. We document 3 cases in Vietnam of desensitization to ASA in patients with coronary artery disease and coexisting ASA hypersensitivity. One of these 3 patients had probable immune-mediated hypersensitivity, whereas the remaining 2 had probable Cox-1-mediated reactions. The regimen of desensitization we employed for each patient was designed to account for the probable mechanism of hypersensitivity in the individual and further modified according to the degree of tolerance observed, with all 3 patients eventually achieving a daily cardioprotective dosage of ASA.
Original language | English (US) |
---|---|
Pages (from-to) | 170-173 |
Number of pages | 4 |
Journal | World Allergy Organization Journal |
Volume | 5 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2012 |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
- Pulmonary and Respiratory Medicine